Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 48 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC) Clear all

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more

Conditions: Small Cell Lung Cancer
Interventions: Venetoclax, Atezolizumab, Carboplatin, Etoposide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions: obrixtamig, atezolizumab, carboplatin, etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Mobile, Alabama • Little Rock, Arkansas • Hialeah, Florida + 13 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Interventions: Bomedemstat, Atezolizumab; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Small Cell Lung Cancer Extensive Stage
Interventions: quaratusugene ozeplasmid, atezolizumab; Biological
Lead sponsor: Genprex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Lone Tree, Colorado • St Louis, Missouri • Canton, Ohio + 9 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: MGC018; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lung Cancer
Interventions: LDE225, Etoposide and Cisplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Obatoclax, Carboplatin/etoposide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Scottsdale, Arizona + 27 more

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Carboplatin, Durvalumab, Etoposide, Olaparib, Radiation Therapy; Drug · Biological · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib; Drug
Lead sponsor: Muhammad Furqan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Ifinatamab Deruxtecan (I-DXd); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Springdale, Arkansas • Jacksonville, Florida • Tampa, Florida + 13 more

Conditions: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions: DJI136; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Lexington, Kentucky • Houston, Texas • Seattle, Washington

Conditions: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions: Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 37
States / cities: Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Iadademstat, Atezolizumab, SBRT; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Tarlatamab, AB248; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 13
States / cities: Gilbert, Arizona • Los Angeles, California • Tampa, Florida + 10 more

Conditions: Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Interventions: 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab; Drug
Lead sponsor: Ariceum Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 16 more

Conditions: Extensive Stage-small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Atezolizumab, Carboplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Extensive-stage Small Cell Lung Cancer
Interventions: Durvalumab, Tremelimumab, SGI-110; Drug
Lead sponsor: Catherine Shu; Other
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Interventions: Carboplatin, Atezolizumab, Etoposide, Total Body Irradiation, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging; Drug · Biological · Radiation + 1 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide); Drug
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 65
States / cities: Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 60 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more

Conditions: Small Cell Lung Carcinoma
Interventions: Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide; Combination Product
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 148
States / cities: Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more

Search by objective public record fields.

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Iadademstat + SBRT With Atezo in ES-SCLC

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study